ERBB2 and neoplasm: Herein, the cytological study results showed that anti-HER antibody drugs, trastuzumab and pertuzumab, as well as small molecule kinase inhibitors, lenatinib, and lapatinib, elicited inhibitory effects on tumor cells harboring ERBB2 p.R678Q mutations [28].